A Randomized, Open Label Study Comparing Safety and Efficacy Parameters for a High and a Low Dose of Ambrisentan (Adjusted for Body Weight) for the Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 09 Oct 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ambrisentan (Primary)
Indications Pulmonary arterial hypertension
Focus Adverse reactions
Sponsors GlaxoSmithKline

Most Recent Events

27 Jun 2019 Status changed from suspended to discontinued.
02 Oct 2018 Planned End Date changed from 19 Nov 2018 to 1 Feb 2019.
02 Oct 2018 Planned primary completion date changed from 19 Nov 2018 to 1 Feb 2019.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight